|
Volumn 26, Issue SUPPL. 2, 2005, Pages 120-122
|
Management of the febrile neutropenic patient
|
Author keywords
Antimicrobial susceptibility; Antimicrobial therapy; Febrile neutropenia
|
Indexed keywords
ANTIBIOTIC AGENT;
QUINOLINE DERIVED ANTIINFECTIVE AGENT;
VACCINE;
ALPHA HEMOLYTIC STREPTOCOCCUS;
ANTIBIOTIC PROPHYLAXIS;
ANTIBIOTIC SENSITIVITY;
ANTIBIOTIC THERAPY;
ANTIMICROBIAL THERAPY;
CATHETER INFECTION;
COAGULASE NEGATIVE STAPHYLOCOCCUS;
CONFERENCE PAPER;
CYTOMEGALOVIRUS INFECTION;
DISEASE DURATION;
DISEASE SEVERITY;
ESCHERICHIA COLI;
EVIDENCE BASED MEDICINE;
FEBRILE NEUTROPENIA;
GRAM NEGATIVE BACTERIUM;
GRAM POSITIVE BACTERIUM;
HIGH RISK PATIENT;
HUMAN;
INFECTION;
INFECTION PREVENTION;
INFECTION RISK;
INTERMETHOD COMPARISON;
INTRAVASCULAR CATHETER;
METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;
MICROBIOLOGY;
MONOTHERAPY;
MYCOSIS;
NONHUMAN;
ONCOLOGY;
OUTPATIENT;
PENICILLIN RESISTANCE;
PNEUMOCYSTIS PNEUMONIA;
PRIORITY JOURNAL;
PSEUDOMONAS AERUGINOSA;
PYREXIA IDIOPATHICA;
RISK ASSESSMENT;
STAPHYLOCOCCUS AUREUS;
TREATMENT INDICATION;
VANCOMYCIN RESISTANT ENTEROCOCCUS;
VIRUS INFECTION;
|
EID: 27744459039
PISSN: 09248579
EISSN: None
Source Type: Journal
DOI: 10.1016/j.ijantimicag.2005.07.010 Document Type: Conference Paper |
Times cited : (11)
|
References (11)
|